Covic A, Goldsmith D J, Farmer C K, Cox J, Dallyn P, Sharpstone P, Kingswood J C
Clinica a IV-a Medicală-Nefrologie, Spitalul Clinic C. I. Parhon, Iaşi.
Rev Med Chir Soc Med Nat Iasi. 1999 Jan-Jun;103(1-2):88-93.
Abnormalities (reduction in/absence of) in diurnal bp rhythm are much more commonly seen in patients with chronic uremia than in patients with primary hypertension or in normal subjects. Target-organ damage is greater in these patients. However, the extent to which these diurnal bp rhythm changes are consistent or variable is untested. We retrospectively examined 223 ambulatory blood pressure monitoring (ABPM) traces in 92 patients with chronic uremia who had undergone ABPM at least twice (mean 2.3 ABPM traces/patient) over the period 1991-1997. ABPM technique and analysis were constant over this period. We found that for patients with chronic declining renal function but not yet on dialysis therapy, 67% retained the same diurnal rhythm from one ABPM recording to the next; if the known tendency for declining renal function to accompanied by a greater prevalence of "non-dipping" is taken into account, 82% of all patients had a "predictable" diurnal pattern. 79% of transplant patients, 87% of haemodialysis patients and 100% of CAPD patients retained the diurnal rhythmicity from one ABPM session to the next. Non-dipping was much more frequent than dipping (67% vs 33%). We conclude that abnormalities of diurnal BP rhythm are reasonably consistent in patients with renal hypertension, especially as renal function declines and patients enter the renal replacement therapy programme.
与原发性高血压患者或正常受试者相比,慢性尿毒症患者更常出现日间血压节律异常(降低/缺失)。这些患者的靶器官损害更严重。然而,这些日间血压节律变化的一致性或变异性程度尚未得到检验。我们回顾性研究了1991年至1997年间92例慢性尿毒症患者的223份动态血压监测(ABPM)记录,这些患者至少接受了两次ABPM检查(平均每位患者2.3份ABPM记录)。在此期间,ABPM技术和分析方法保持不变。我们发现,对于肾功能慢性下降但尚未接受透析治疗的患者,67%的患者从一次ABPM记录到下一次记录时保持相同的日间节律;如果考虑到肾功能下降往往伴随着更高的“非勺型”发生率这一已知趋势,那么82%的患者具有“可预测”的日间模式。79%的移植患者、87%的血液透析患者和100%的持续性非卧床腹膜透析(CAPD)患者从一次ABPM检查到下一次检查时保持日间节律。非勺型比勺型更为常见(67%对33%)。我们得出结论,肾性高血压患者的日间血压节律异常具有相当的一致性,尤其是随着肾功能下降以及患者进入肾脏替代治疗阶段。